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Introduction. Pakistani population has a very rich anthrogeneological background with waves of migration from neighboring
regions.IncidenceratesofbreastandovariancancerinPakistanareonsucharapidrisethatitisnecessarytocheckthecontributory
factors, genetic and nongenetic. An insight into the prevalence data emphasizes the formulation of a BRCA1 and BRCA2 database
forthePakistanipopulation.Method.In thisstudy conducted byauthors,datafromdiagnosedcasesofboth sporadicandinherited
female breast and ovarian cancer cases was gathered after performing molecular genetic analysis by screening for alterations in
the coding sequence of the BRCA gene. The region of interest was analyzed by the aid of various molecular biology tools such
as automated DNA sequencer. Bioinformatics software was used to interpret the results, and database was prepared. Results.
Mutational screening of the exons in all the samples of our study group did not reveal any pathogenic mutation. These results
along with the results of the previous Pakistanistudies for both BRCA1 and BRCA2 genes were summed up to prepare a Pakistani
database. Percentage involvement of these genes was estimated. Nine percent of these cancers show alterations in BRCA1 gene
w h i l e3p e r c e n th a v es h o w nBRCA2 variants. The remaining 88 percent of breast and ovarian cancers can be attributed to the
involvement of other genes.
1.Introduction
Breast cancer is the most prevalent cancer in the world,
and ovarian cancer is the sixth most common cancer in
the world [1]. Inherited mutations in the breast cancer
susceptibility gene 1 (BRCA1) [MIM 113705] and breast
cancer susceptibility gene 2 (BRCA2) [MIM 600185] are
associated with a high risk of developing breast and ovarian
cancers in females of diﬀerent age and ethnic groups. These
well-deﬁned high-penetrance genes show loss-of-full func-
tion germ line mutations in hereditary cases and decreased
expression in sporadic tumors [2–4]. Approximately, 5 to 10
percent of breast cancer [5] and at least 10 percent of ovarian
cancers [6] are hereditary. Sequence variation in the BRCA1
gene accounts for 45 percent of inherited breast cancer and
more than 90 percent of inherited breast and ovarian cancer
[3], and both genes combined account for only 25 percent of
familial risk [7].
The spectrum of mutationsin these genes varies between
populations, with some showing a high frequency of unique
mutations[8].Manysuchalterationsmayberecurrent, often
being identiﬁed in isolated populations as the results of
af o u n d e re ﬀect [5]a n dm a yb et h eb a s i so fd i ﬀerences
in cancer risk between populations [9]. Ashkenazi Jewish,
Norwegian, Dutch, and Icelandic people have a higher rate
of certain genetic alterations in BRCA1 [10].
1.1. BRCA1 and BRCA2 Screening in Asia. Most of BRCA1
and BRCA2 research has been focused on the Caucasian
populations; however, the allelic frequency of higher pen-
etrance genes in the Asian population may be higher than
that in Caucasian population [11]. Immigrant Asian women
especially from South Asia who are settled in the West show
high rates of these cancers. Risch et al. [12] reported greater
frequencies of mutations among cases of ovarian cancer
that were of Indo-Pakistani descent than among British or2 Journal of Oncology
mixed northern- or western-European ethnicity in Ontario,
Canada.
Although 60 percent of the world’s population resides in
the Asian continent, and the fact that the Chinese, Malays,
and Indians are three major Asian haplogroups, genetic
predisposition to hereditary diseases and the applicability of
genetic testing in these diverse ethnic groups is still unclear
[13]. These regions have high rates of both these cancers
especially the developing South Asian countries.
1.2. BRCA1 and BRCA2 Screening in Pakistani Population.
Amongst the Asian countries, Pakistan has one ofthe highest
rates of breast and ovarian cancer [14] with breast cancer
beingthemostcommonandovarianthethirdmostcommon
malignancy amongst Pakistani women [15]a n dt h em o s t
common cancer of gynecological origin in Pakistan [16]. A
nine-year study period at a tertiary care cancer institution
in Karachi, Pakistan showed that breast cancer was the most
common cancer in females accounting for 38.2 percent of
total cancer cases, at rates almost highest in Asia and ovarian
canceraccountingfor 4.9percent [17].Incidenceratesin this
regionare onsuch arapid rise thatitisnecessary tocheckthe
contributory factors, genetic and nongenetic. An insight into
the above data emphasizes the formulation of a BRCA1 and
BRCA2 database for the Pakistani population.
2.Methodology
Studyconductedby authors was carried outat the Centre for
Research in Applied and Experimental Medicine, National
University of Science and Technology, Rawalpindi. This
study focused on mutational screening of BRCA1 gene in
diagnosed cases of both hereditary and sporadic breast and
ovarian cancer. In course of BRCA1 gene screening, all exon-
intron boundaries were sequenced.
These patients were interviewed after reviewing the his-
tory of their disease. Questionnaire was ﬁlled out containing
information of their personal, family, and disease history.
Ethnicityofeachcandidatewasnotedwith theaim ofﬁnding
founder eﬀect mutations clustered to a speciﬁc ethnic group.
Organic phenol-chloroform extraction method [18]w a s
used to extract the genome. Ampliﬁcation of all the exon-
intron boundaries of BRCA1 gene by polymerase chain
reaction (PCR) was performed using the oligonucleotide
primers designed from the intronic sequences of the gene.
Puriﬁed products were subjected to DNA sequencing by
Automated Genetic Analyzer, Beckman Coulter CEQ8000,
Genetic Analysis System. Alignment and mutational analysis
was done using Bioedit software [19]. The sequencing
chromatograms of the aﬀected individuals were compared
with the corresponding control full length gene sequences
from UCSC Genome Browser [20] database to identify the
aberrant nucleotide base pair change. Ensembl [21] database
was used to recheck the gene sequence for cDNA and mRNA
information.
Previously, four Pakistani studies depicted the muta-
tional spectrum of these two genes. Two major pioneering
investigations were accomplished by Liede et al. [22]a t
the National Cancer Institute, Karachi and Jinnah Hospital,
Lahore and by Rashid et al. [14]a tt h eS h a u k a tK h a n u m
Memorial Hospital, Lahore. A comparatively small study
focusing on mutational analysis of BRCA1 gene was per-
formed by Malik et al. [23] at the COMSATS Institute of
Information Technology, Islamabad.
Liede et al. [22] conducted a case-control study of 341
case subjects with breast cancer, 120 case subjects with
ovarian cancer, and 200 female control subjects. Human
genomic DNA was isolated from peripheral blood. Exon-
intron boundaries were screened by protein-truncation
testing (PTT). Direct sequencing was used for conﬁrmation
of all mutant bands detected by PTT.
Rashid et al. [14] selected patients from 176 breast
and/or ovarian cancer families who were diagnosed with
invasive breast or epithelial ovarian cancer. Genomic DNA
was extracted from blood samples. The entire coding
regions of the BRCA1 and BRCA2 genes were screened
using single strand conformational polymorphism (SSCP)
analysis, denaturing high pressure liquid chromatography
(DHPLC) analysis, and the protein truncation (PTT) assay
[14]. Automated DNA Sequencing was performed for each
sample revealing variants by SSCP, DHPLC, or PTT.
150casesofunilateralbreastcancerpatientswereselected
by Malik et al. [23]. After DNA extraction, Single strand
conformational polymorphism (SSCP) was done for exons
of BRCA1, and sequence analysis was performed for putative
sequence variant.
3.Results
The results of samples recorded on BIORAD gel documen-
tation system showed good yield and ampliﬁcation of the
DNA with the primers. The chromatograms of BRCA1 gene
from aﬀected patients (Figure 1) after mutational screening
of the exons in all the samples of our study group revealed
no pathogenic sequence variant correlating with breast or
ovarian cancer pathogenesis. This is suggestive of the need
to focus on the role of other high- or low-penetrance genes
in breast and ovarian cancer predisposition in Pakistani
population.
By adding present and previous results regarding both
BRCA1 and BRCA2 genes, a database with new percentage
prevalence was formed. The role of BRCA1 and BRCA2 in
the pathogenesis of breast and ovarian cancer in Pakistan
was noted, and the most prevalent Pakistani mutations were
highlighted.
3.1. Percentage of BRCA1 BRCA2 Mutations in Breast and
Ovarian Cancer Patients in the Pakistani Population. Liede
et al. [22] identiﬁed 42 sequence variants harboring 31
BRCA1 mutations and 11 BRCA2 variants in their study
groupof341women with breast cancerand 120women with
ovarian cancer. Rashid et al.[14]studied 176Pakistani breast
and ovarian cancerpatientsselectedonfamily history and on
age of diagnosis and identiﬁed a total of 30 sequence variants
and among them 23 deleterious mutations in BRCA1 and 7
mutations BRCA2 gene. Malik et al. [23] detected a total of 6
variants in their samples (Tables 1 and 2). Taking all studies
together, a total of 643 probands have been ascertained.Journal of Oncology 3
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Figure 1: A representative chromatogram generated by automated genetic analyzer, Beckman Coulter CEQ TM, 8000 sequencing of Ex 13
ofBRCA1 gene from an aﬀected patient. Region between the two arrows indicates the exonic sequence. Flanking region is intronic sequence.
MutationsinBRCA1 and BRCA2 were found, respectively, in
nine and three percent of breast and ovarian cancer patients
(Figure 2).These resultsare authenticatedby Risch etal.[12]
who reported a high frequency of BRCA1 mutations among
cases of ovarian cancer that were of Indo-Pakistani descent
(14%) along with Jewish (21%) and Italian (17%) ancestry
in a population-based study of 649 cases of ovarian cancer
in Ontario, Canada. These prevalence percentages highlight
the signiﬁcance of this review relevant to the Pakistani
population. The remaining 88 percent of breast and ovarian
cancers can be attributed to the involvement of other genes
such as tumor protein (TP53) [MIM 191170], phosphatase
and tension homolog (PTEN) [MIM 601728], checkpoint
kinase 2 (CHEK2) [MIM 604373], and estrogen Receptor 1
(ESR) [MIM 133430].
3.2. Most Prevalent BRCA1 and BRCA2 Mutations in the
Pakistani Population. Twenty one distinct BRCA1 mutations
were observed by Liede et al. [22]w h i c ha r em o s t l y
insertions, deletions, or point mutations and exon 11, the
l a r g e s te x o no ft h eg e n e ,w a sm a i n l yf o u n dt ob et h ed i s e a s e
causing region. One intronic variant in exon 14 (IVS14-
1G→A) was also noted (Table 1). Ten distinct types of
BRCA2 variants were detected by these researchers, 9 in
exon 11, and only one in exon 22, the 9140delA mutation
in a Muhajir breast cancer patient (Table 2). The BRCA2
3337C→T mutation was found in two patients. Five BRCA1
mutations(2080insA,3889delAG,4184del4,4284delGA,and
IVS14-1ArG) and one BRCA2 mutation (3337C→T) were
identiﬁedinmultipleunrelatedcasesubjectsandrepresented
candidate founder mutations. Rashid et al. [14]r e p o r t e da
total of twenty-two distinct mutations, 15 distinct variants
in BRCA1, and 7 distinct variants in BRCA2.A m o n gt h e s e
were 12 frame shift mutations, 8 nonsense mutations, and 2
splice-site mutations (Tables 1 and 2). The most commonly
observed BRCA1 mutation was the 4627C→A, nonsense
mutationidentiﬁed in5 families. Fourmutations, 185delAG,
185insA, 4627C→A, and 5622 C→T, were recurrent; these4 Journal of Oncology
Table 1: Mutational spectrum of BRCA1 gene in Pakistani population.
No Exon
no. Point of mutation Mutation Ethnicity Reference
Deletion
Type
1 2 185delAG frameshift and truncation 1P u n j a b i
2P a t h a n
Liede et al. [22]
Rashid et al. [14]
2 11 1616delAAAT frameshift and truncation 1 Muhajir Liede et al. [22]
3 12 4284delAG frameshift and truncation 2 Muhajir Liede et al. [22]
4 11 4184del4 frameshift and truncation 3P u n j a b i
1S i n d h i Liede et al. [22]
5 11 1476delG frameshift and truncation 1 Punjabi Liede et al. [22]
6 11 3889delAG frameshift and truncation 2 Punjabi Liede et al. [22]
7 11 2388delG frameshift and truncation 2 Muhajir Liede et al. [22];
Rashid et al. [14]
8 11 894delG frameshift and truncation 1 Muhajir Liede et al. [22]
9 11 1956delA frameshift and truncation 1 Punjabi Liede et al. [22]
10 11 1127delA frameshift and truncation 1 Punjabi Liede et al. [22]
11 11 2266delG frameshift and truncation 1 Punjabi Liede et al. [22]
12 7 550delA frameshift and truncation 1 Multiracial Rashid et al. [14]
13 8 589delCT frameshift and truncation 1 Punjabi Rashid et al. [14]
14 17 5149delCTAA frameshift and truncation 1 Punjabi Rashid et al. [14]
15 11 1013delTG frameshift and truncation 1 Muhajir Liede et al. [22]
Insertion
Type
16 11 2080insA frameshift and truncation 3 Pathan Liede et al. [22]
17 11 2041insA frameshift and truncation 2 Punjabi Liede et al. [22]
18 2 185insA frameshift and truncation 4 Punjabi Liede et al. [22];
Rashid et al. [14]
19 11 1770insT frameshift and truncation 1 Balouchi Liede et al. [22]
20 11 3812insT frameshift and truncation 1 Multiracial Rashid et al. [14]
21 20 5376insA frameshift and truncation 1 Multiracial Rashid et al. [14]
22 13 4356insA frameshift and truncation 3N o t
speciﬁed Malik et al. [23]
Nonsense
Protein changed
23 15 4627C→A, S1503X Stop 1503 6 Punjabi
Liede et al. [22];
Rashid et al. [14]
24 11 1590 C→T, Q491X Gln to stop 1 Punjabi Rashid et al. [14]
25 11 1731C→T, Q531X Gln to stop 1 Multiracial Rashid et al. [14]
26 12 4302C→T, Q1395X Gln to stop 1 Punjabi Rashid et al. [14]
27 24 5622C→T, R1835X Arg to stop 2 Punjabi Rashid et al. [14]
28 11 1912T→G Gln to stop 1 Muhajir Liede et al. [22]Journal of Oncology 5
Table 1: Continued.
No Exon
no. Point of mutation Mutation Ethnicity Reference
Missense
Protein changed
29 13 4305 Serine changed 3N o t
speciﬁed Malik et al. [23]
30 11 3405C→TC →T1 M u h a j i r L i e d e e t a l . [ 22]
31 11 2722C→GC →G1 K a s h m i r i L i e d e e t a l . [ 22]
Splice site
32 Intron
14 IVS14-1G→A 2P u n j a b i
1P a t h a n Liede et al. [22]
33 Intron
4 IVS4-1G→T 1 Punjabi Rashid et al. [14]
34 Intron
20 IVS20-1G→C 1 Multiracial Rashid et al. [14]
Table 2: Mutational spectrum of BRCA2 gene in Pakistani population.
No Exon
no. Point of mutation Mutation Ethnicity Reference
Type of mutation
Deletion
1 22 9140delA frameshift and
truncation 1M u h a j i r L i e d ee ta l .[ 22]
2 11 3913delG frameshift and
truncation 1 Sindhi Liede et al. [22]
3 11 5950delCT frameshift and
truncation 1P u n j a b i L i e d ee ta l .[ 22]
4 11 6696delTC frameshift and
truncation 1P u n j a b i L i e d ee ta l .[ 22]
5 11 2674delG frameshift and
truncation 1M u h a j i r L i e d ee ta l .[ 22]
6 11 5057delTG frameshift and
truncation
1P u n j a b i
1P a r s i
Liede et al. [22];
Rashid et al. [14]
7 11 3179delA frameshift and
truncation 1M u h a j i r L i e d ee ta l .[ 22]
8 10 1993delAA frameshift and
truncation 1 Multiracial Rashid et al. [14]
9 11 4052delTAGA frameshift and
truncation 1 Multiracial Rashid et al. [14]
10 25 9658delT frameshift and
truncation 1 Multiracial Rashid et al. [14]
Insertion
11 11 5302insA frameshift and
truncation 1P u n j a b i L i e d ee ta l .[ 22]
12 11 6679insAA frameshift and
truncation 1P u n j a b i L i e d ee ta l .[ 22]
Nonsense
Protein changed
13 11 3337C→T Gln to stop 2 Memon Liede et al. [22]
14 10 2083C > T, Q619X Gln to stop 1 Punjabi Rashid et al. [14]
15 11 3218T > G, L992X Leu to stop 1 Multiracial Rashid et al. [14]
16 11 5962G > T, E1912X Glu to stop 1 Multiracial Rashid et al. [14]6 Journal of Oncology
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Figure 2: Genes involved in pathogenesis of breast and ovarian
cancer in Pakistanipopulation.
accounted for 52 percent of all identiﬁed BRCA1 mutations.
Malik et al. [23] observed two types of mutations in BRCA1,
one insertion and one nonsense variant (Tables 1 and
2). Mutational analysis of all these studies emphasizes the
justiﬁcation of genetic testing for predisposing BRCA1 germ
line mutations for any Pakistani family with multiple female
breast and/or ovarian cancer cases [14].
In total, BRCA1 variant 4627C→Aw a so b s e r v e di n2 2
percent of the probands showing recurrent mutations and
features as the most prevalent BRCA1 mutation in Pakistani
population (Figure 3), while 15 percent of these patients
showed the 4184del4 BRCA1 variant which appears to be
the second most prevalent mutation in Pakistani population
(Figure 4). BRCA2 mutational analysis revealed 3337C→T
and 5057delTG to be equally prevalent (50 percent each) in
the study participants showing recurrent BRCA2 variants.
3.3. BRCA1 and BRCA2 Mutation Prevalence in Diﬀerent
Ethnic Groups of Pakistan. Pakistan has a pivotal location
on the map of Asia, being at the crossroads of South
Asia,theMiddle East,a n dCentral Asia. Pakistani population
has a very rich anthrogeneological background owing to
successive waves of invasions and adaptation of diﬀerent
haplogroups including Persians, Aryans, Mongols, Sikhs,
Arabs, Greeks, Turks,a n dt h eBritish. Massive migrations
from India in 1947 and more recently from Afghanistan have
contributed to further diversifying the Pakistani population.
These diﬀerent populations are settled in four provinces
of Pakistan. Punjabis comprise the largest ethnic group in
the country at 44.15 percent, while other important ethnic
groups include Pashtuns (15.42 percent), Sindhis (14.1
percent), Seraikis (10.53 percent), Muhajirs (7.57 percent),
Balouchis (3.57percent), and others (4.66percent) [24]. The
diverse ethnic blend concentrated in this region, especially in
urban regions, contributes greatly to the genetic variability
for inheritance of breast and ovarian cancer.
11%
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Figure 3: Most prevalent recurrent BRCA1 mutations in Pakistani
population.
3337C→T
5057delTG
Figure 4: Most prevalent recurrent BRCA2 mutations in Pakistani
population.
ThetwomajorstudiesofLiedeetal.[22]andRashidetal.
[14] included ethnicity as a vital determinant of mutational
screening. In the 54 BRCA1 mutations of both of these
studies, 31 (57%) were found in the Punjabi ethnic group.
Amongst the 18 BRCA2 variants of both these studies, 6
(33%) were of Punjabi origin. Hence, the Punjabi ethnic
group showed maximum sequence variants in the BRCA
gene variants (Table 3).
3.4. Candidate Founder Mutations of BRCA1 and BRCA2 for
the Pakistani Population. Twelve of the 21 BRCA1 mutations
(57 percent) and 8 of the 10 BRCA2 mutations (80 percent)
detected by Liede et al. [22]w e r eu n i q u et ot h eP a k i s t a n i
population [22], while Rashid et al. [14] detected ten
mutations (33 percent) which were unique to the Pakistani
population, which is comprised of 5 BRCA1 mutations (33
percent) and 5 BRCA2 mutations (71 percent). The ﬁnding
of thirteen recurrent BRCA1 and two recurrent BRCA2Journal of Oncology 7
Table 3: Ethnic distribution of BRCA carriers in Pakistani popula-
tion.
BRCA1 mutations BRCA2 mutations
Ethnicity % Ethnicity %
Punjabi 57 Punjabi 33
Muhajir 17 Multiracial 28
Pathan 13 Muhajir 17
Sindhi 1.8 Memon 11
Balouchi 1.8 Parsi 5.5
Kashmiri 1.8 Sindhi 5.5
Multiracial 7.4
mutations in some members of the Pakistani population
could allow very economical screening for such mutations in
speciﬁc ethnic groups in the country which could be of great
beneﬁt to public health measures.
The most prevalent BRCA1 mutation of both studies
combined, 4627C→A, was found in six Punjabi patients
increasing the likelihood of ﬁnding this variant in Punjabi
ethnicity. Four probands showed the 4184del4 BRCA1
variant out of which three were Punjabi and one Sindhi. All
the four carriers of the BRCA1 185insA and the two carriers
ofthe BRCA1 5622C→T were also ofPunjabi ethnicity.This
predisposition of the Punjabis to maximum BRCA variants
can lead to focusing on the speciﬁc sequence variants of
this ethnic group. All the carriers of the BRCA1 2080insA
mutation were of Pathan ethnicity. Rashid et al. [14]a l s o
found 185delAG in two non-Jewish unrelated Pakistani
carriers of Pathan ethnicity, whose ancestors originated from
the same geographic region in the North-West Frontier
Province of Pakistan. These two mutations can be the focus
of candidate founder mutations in this ethnic group. The
two cases with the BRCA1 4284delAG mutation belonged to
the Muhajir ethnic group, again signifying the importance of
focusing on this mutation in this particular ethnic group.
In BRCA2 screening, Liedeet al. [22]found the recurrent
3337C→T variant in two Memon breast cancer patients
pointing towards the signiﬁcance of ﬁnding this mutation in
other Memon patients as well. 5057delTG BRCA2 mutation
was a ﬁnding of both studies; Rashid et al. [14] detected this
mutationinaPunjabi patient,while Liedeetal. [22]detected
it in a minority ethnic group, a Parsi ovarian cancer patient.
3.5. Possible Management Strategies. Ever since the discovery
of breast and ovarian cancer genes, many advances in clinical
research have been made which provide the rationale for
moving genetic testing of these genes into clinical practice
[25]. BRCA1 and BRCA2, like other genes, have not only
served as molecular markers for hereditary breast cancer
risk screening but also become important indicators for
breast cancer prevention, treatment, and prognosis [26].
Genetictestingisgaining acceptanceworldwideandhasbeen
established throughout North America and much of Europe.
Geneticcounseling,especiallyincountrylikePakistanhaving
oneofthehighestrates ofconsanguinity [27,28],ispracticed
bymany healthprofessionals; however, itsexpansion into the
health policy and training regimes of health care providers is
needed. The awareness, however, of genetic testing as a tool
for preventive and treatment-oriented management of these
tumorsislimited.FormulationofBRCA mutationaldatabase
can serve as a cost-eﬀective tool to identify individuals
at high risk such as unaﬀected carrier relatives who have
a defective allele that can be transferred to oﬀspring.
Such tests are strategized on the basis of most prevalent
mutations in a particular population/ethnic group that can
save both time and money. Till then the most eﬀective
options for breast cancer risk reduction include prophylactic
bilateral mastectomy [29] prophylactic oophorectomy, and
oral administration of Tamoxifen [26] in some countries. If
genetic testing for these genes becomes streamlined, these
prophylactic procedures and other preventive strategies will
be warranted to become routine for mutation carriers along
with vigilantmedicalcheckups,especially inaneconomically
challenged country like Pakistan.
4.Conclusions
The need for larger collaborative studies between medical
professionalsand molecularbiologistscannotbeemphasized
enough. This is necessary for gaining further insight into
mutational spectra and ethnic distribution of diﬀerent types
of mutations, in a search for founder eﬀect mutations, which
can become a part of cancer screening policies in Pakistan.
The high prevalence of these cancers and the presence
of recurrent mutations of these genes in the Pakistani
population,especiallytheobservationofahighpercentageof
BRCA1 variants in ovarian cancer cases, emphasize the need
for improving genetic counselingstrategies and makegenetic
testing a part of screening policies. The more work done on
the genomics of this disease with relevance to the Pakistani
population, the closer a genetic cure targeted for this speciﬁc
population can be found.
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